A Phase 3 interventional study of CHS-1420 and Adalimumab in Plaque Psoriasis, sponsored by Coherus Biosciences, Inc.. Completed at 99 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Coherus Biosciences, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.
Among the 764 studies in Psoriasis with a site in United States, this one is the 81st largest by enrollment of the 673 interventional ones that give a count, is one of 44 that started in 2015, is one of 188 in phase 3, and was the 362nd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
InventisBio Co., Ltd · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
764 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 98 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 44 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 545 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 673 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 375 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
524 of 764 have an industry lead sponsor. The 10 most frequent:
Coherus Biosciences, Inc. is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Coherus Biosciences, Inc. has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
22 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 764 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.
This is a 55-week, randomized, double-blind, active-control, parallel group, multicenter, global study in subjects with active, moderate to severe, chronic PsO.
The study will consist of 24 weeks of administration of blinded study drug, divided into Treatment Period 1 and Treatment Period 2, then 23 weeks of administration of open-label CHS-1420 and a Follow-up visit 8 weeks after the last dose. Subjects who meet inclusion/exclusion criteria will be stratified by body mass index (BMI), and age and randomized 1:1 to receive CHS-1420 or Humira in Treatment Period 1. Subjects assigned to CHS-1420 will continue to receive CHS-1420 in Period 2. Subjects assigned to Humira in Period 1 will be randomly assigned (1:1) to either continue with Humira in Treatment Period 2 or to switch to CHS-1420 in Treatment Period 2. All subjects will receive open label CHS-1420 in Treatment Period 3.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Adalimumab (Humira) 40mg 2 doses at week 0/Day 0, then 1 dose every 2 weeks starting at Week 1 until Week 15. At Week 16 subjects initially randomized to adalimumab will be assigned (1:1) to CHS-1420 or continue adalimumab treatment, 1 dose every 2 weeks for weeks 17-23. The assignments for treatment sequences (Treatment Period 1 and Treatment Period 2) were made randomly at the beginning of Treatment Period 1. At week 24 subjects will switch to CHS-1420 open label until study end.
Drug: CHS-1420 · Drug: Adalimumab
CHS-1420 40mg 2 doses at Week 0/Day 0 then 1 dose every 2 weeks starting at Week 1 for 23 weeks. At Week 24 subjects will continue on to CHS-1420 open label until study end.
Drug: CHS-1420
Also known as: Humira
Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12
The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.
Time frame: 12 weeks
| Milestone | CHS-1420 | Humira (Adalimumab) Reassigned to CHS-1420 | Humira (Adalimumab) |
|---|---|---|---|
| Started | 274 | 135 | 136 |
| Completed | 220 | 101 | 117 |
| Not completed | 54 | 34 | 19 |
The efficacy success criterion was the equivalence between CHS-1420 and Humira at Week 12. Equivalence was based upon 2-sided 95% confidence interval (CI) for the difference between the proportions of subjects in the CHS-1420 and Humira groups achieving PASI-75 at Week 12. If the 95% CI lay entirely within the interval (-15%, 15%), equivalence was established.
| Participants | Humira (Adalimumab) | CHS-1420 |
|---|---|---|
| Difference Between the Percentage of Subjects in Each Treatment Group Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI-75) at Week 12 | 203 | 211 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period 1: CHS-1420 | 0/274 (0%) | 4/274 (1.5%) | 41/274 (15%) |
| Treatment Period 1: Humira (Adalimumab) | 0/271 (0%) | 6/271 (2.2%) | 38/271 (14%) |
| Treatment Period 2: CHS-1420/CHS-1420 | 0/255 (0%) | 4/255 (1.6%) | 0/255 (0%) |
| Treatment Period 2: Humira/CHS-1420 | 0/126 (0%) | 3/126 (2.4%) | 0/126 (0%) |
| Teatment Period 2: Humira/Humira | 0/130 (0%) | 1/130 (0.8%) | 0/130 (0%) |
| Treatment Period 3: Open Label CHS-1420 Extension | 1/474 (0.2%) | 4/474 (0.8%) | 0/474 (0%) |
| Event | Treatment Period 1: CHS-1420 | Treatment Period 1: Humira (Adalimumab) | Treatment Period 2: CHS-1420/CHS-1420 | Treatment Period 2: Humira/CHS-1420 | Teatment Period 2: Humira/Humira | Treatment Period 3: Open Label CHS-1420 Extension |
|---|---|---|---|---|---|---|
| Anal fistulaGastrointestinal disorders | 0/274 | 0/271 | 0/255 | 1/126 | 0/130 | 0/474 |
| BronchitisInfections and infestations | 0/274 | 0/271 | 0/255 | 1/126 | 0/130 | 0/474 |
| Lobar pneumoniaInfections and infestations | 0/274 | 0/271 | 0/255 | 1/126 | 0/130 | 0/474 |
| Calculus uretericRenal and urinary disorders | 0/274 | 0/271 | 0/255 | 1/126 | 0/130 | 0/474 |
| TuberculosisInfections and infestations | 0/274 | 0/271 | 0/255 | 0/126 | 1/130 | 0/474 |
| GastritisGastrointestinal disorders | 0/274 | 0/271 | 1/255 | 0/126 | 0/130 | 0/474 |
| Inguinal HerniaGastrointestinal disorders | 0/274 | 0/271 | 1/255 | 0/126 | 0/130 | 0/474 |
| Limb injuryInjury, poisoning and procedural complications | 0/274 | 0/271 | 1/255 | 0/126 | 0/130 | 0/474 |
| ObesityMetabolism and nutrition disorders | 0/274 | 0/271 | 1/255 | 0/126 | 0/130 | 0/474 |
| DiarrheaGastrointestinal disorders | 0/274 | 1/271 | 0/255 | 0/126 | 0/130 | 0/474 |
| Event | Treatment Period 1: CHS-1420 | Treatment Period 1: Humira (Adalimumab) | Treatment Period 2: CHS-1420/CHS-1420 | Treatment Period 2: Humira/CHS-1420 | Teatment Period 2: Humira/Humira | Treatment Period 3: Open Label CHS-1420 Extension |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 24/274 | 24/271 | 0/255 | 0/126 | 0/130 | 0/474 |
| Upper respiratory tract infectionInfections and infestations | 17/274 | 14/271 | 0/255 | 0/126 | 0/130 | 0/474 |
| Age, Categorical(Participants) | CHS-1420 | Humira (Adalimumab) Reassigned to CHS-1420 | Humira (Adalimumab) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 256 | 124 | 127 | 507 |
| >=65 years | 18 | 11 | 9 | 38 |
| Sex: Female, Male(Participants) | CHS-1420 | Humira (Adalimumab) Reassigned to CHS-1420 | Humira (Adalimumab) | Total |
|---|---|---|---|---|
| Female | 82 | 31 | 38 | 151 |
| Male | 192 | 104 | 98 | 394 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Aug 2015, a primary completion of May 2016 and a completion of Mar 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2019, 3 years 5 months after primary completion. A results delay was requested in May 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Coherus Biosciences, Inc.